Abstract: The present disclosure provides a composition comprising a compound of formula (I) or a physiologically acceptable salt thereof, in which the compound of formula (I) or a physiologically acceptable salt thereof has a HPLC purity of ?90%; wherein R1, R2, X and n are as defined herein. The present disclosure further provides use of the composition according to the present disclosure for preparing and/or purifying a composition comprising a salt of the compound of formula (I), and a method for treating a disease caused by a Coronavirus which comprises administering the composition of the present disclosure to a subject. The composition of the present disclosure comprises the compound of formula (I) with high purity, and has good fluidity and anti-caking property; moreover, the claimed composition comprising the compound of formula (I)) with high purity is more suitable for preparing a composition comprising a salt of the compound of formula (I) with higher purity.

Abstract: The present invention provides a composition comprising a compound of formula (I) or a physiologically acceptable salt thereof, in which the compound of formula (I) or a physiologically acceptable salt thereof has a HPLC purity of ?90%; wherein R1, R2, X and n are as defined herein. The present invention further provides use of the composition according to the present invention for preparing and/or purifying a composition comprising a salt of the compound of formula (I), and a method for treating a disease caused by a coronavirus which comprises administering the composition of the present invention to a subject. The composition of the present invention comprises the compound of formula (I) with high purity, and has good fluidity and anti-caking property; moreover, the claimed composition comprising the compound of formula (I)) with high purity is more suitable for preparing a composition comprising a salt of the compound of formula (I) with higher purity.

Abstract: The present disclosure provides a crystal form comprising a compound of Formula (I) and fumaric acid, wherein the crystal form satisfies at least one of the following conditions: (1) a particle size D90 of the active pharmaceutical ingredient ranges from about 5 ?m to about 60 ?m; and (2) a particle size D50 of the active pharmaceutical ingredient does not exceed about 30 ?m; a pharmaceutical composition containing the crystal form, and a method for treating coronavirus-induced diseases by using the crystal form. The crystal form of the present disclosure enables the pharmaceutical composition containing the crystal form to have advantages such as a higher dissolution rate, a higher dissolution, and the like.

Abstract: The present invention provides a composition comprising a compound of formula (I) or a physiologically acceptable salt thereof, in which the compound of formula (I) or a physiologically acceptable salt thereof has a HPLC purity of ? 90%; wherein R1, R2, X and n are as defined herein. The present invention further provides use of the composition according to the present invention for preparing and/or purifying a composition comprising a salt of the compound of formula (I), and a method for treating a disease caused by a coronavirus which comprises administering the composition of the present invention to a subject. The composition of the present invention comprises the compound of formula (I) with high purity, and has good fluidity and anti-caking property; moreover, the claimed composition comprising the compound of formula (I)) with high purity is more suitable for preparing a composition comprising a salt of the compound of formula (I) with higher purity.

Abstract: The present disclosure provides an active pharmaceutical ingredient containing a crystal form including a compound of Formula (I) and fumaric acid. An X-ray powder diffraction pattern of the crystal form obtained by using Cu-K? radiation includes at least three peaks selected from the group consisting of 10.94°±0.2° 2?, 19.06°±0.2° 2?, 23.50°±0.2° 2?, and 24.66°±0.2° 2?; a particle size D90 of the active pharmaceutical ingredient is smaller than or equal to 20 ?m, and a particle size D50 of the active pharmaceutical ingredient is smaller than or equal to 10 ?m.

Abstract: The present disclosure provides a crystal form of a compound and fumaric acid, an active pharmaceutical ingredient and a pharmaceutical composition containing the same, and a method for treating coronavirus-induced diseases a using the same. In particular, the crystal form of the present disclosure comprises the compound of Formula (I) and fumaric acid, and the X-ray powder diffraction pattern of the crystal form obtained using Cu-K? radiation includes at least three peaks selected from the group consisting of: 0.94°±0.2° 2?, 19.06°±0.2° 2?, 23.50°±0.2° 2?, and 24.66°±0.2° 2?. The crystal form of the present disclosure has a high purity, good stability, and a high melting point.